Sapience Therapeutics is seeking partners for discovery, licensing, and co-development opportunities.
For inquiries and further information, please contact:
Barry Kappel, Ph.D., MBA firstname.lastname@example.org
Our PADS platform enables discovery peptide-antagonists to targets of our choosing entities.
The drugs in our pipeline are designed to disrupt specific protein-protein interactions, which allows the targeting of intracellular proteins previously viewed as undruggable.